Brooke Dunlavy
Family Medicine · Tulsa, OKNPI 1730440603
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 403 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 55 manufacturers reported payments, led by AbbVie at 34.0% of the total. 2025 is the largest year on record at $1,926, 2.4 times the $807 reported in 2019.
Across 403 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$512
- Novo Nordisk$434
- Amgen$428
- Lilly USA, LLC$349
- AstraZeneca$327
- plus $2K from 49 others
Across 17 payments — averaging $33,260 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$312K
- Vertex$125K
- Pfizer$112K
- Boehringer Ingelheim$12K
- Boehringer Ingelheim International GmbH$5K
What the payments were for
- Speaking & faculty fees$5108%
- Food & beverage$5,57490%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,179 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $10,735 |
| Novolog FlexpenInsulin Aspart | 13 | $1,023 |
| Trimethoprim | 12 | $755 |
| Potassium Chloride | 34 | $551 |
| Atorvastatin Calcium | 44 | $363 |
| Pantoprazole Sodium | 37 | $341 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $322 |
| Levothyroxine Sodium | 47 | $251 |
| Omeprazole | 31 | $204 |
| Mirtazapine | 12 | $183 |
| Simvastatin | 31 | $144 |
| Prednisone | 11 | $143 |
| Amlodipine Besylate | 28 | $122 |
| Gabapentin | 16 | $117 |
| Lisinopril | 17 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $512 | $10,73512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Tulsa
- Geoffrey PlumleeTulsa$297K
- Kimberly HuttonTulsa$76K
- Sarah HallTulsa$52K
- Candy TingTulsa$28K
- Scott GhereTulsa$27K
- Michael MaddoxTulsa$24K
- Randall HerbelTulsa$23K
- Chandan LadTulsa$22K
- Scott SexterTulsa$21K
- Scott KochTulsa$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.